ACHE and Alzheimer disease: In this case, it would be inappropriate to simply target cholinergic transmission systemically (e.g., pharmacologically), as this would not differentiate between the vulnerable midbrain AChE-containing neurons (not all of which release ACh) and cholinergic interneurons and lower motor neurons that do not readily degenerate in AD [31].